A5009641083- Pulmonary Hypertension Research and Treatments
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- HIV-related health complications and treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Extracellular vesicles in disease
- Drug-Induced Adverse Reactions
- Advanced MRI Techniques and Applications
- Cardiac Imaging and Diagnostics
- Ultrasound and Hyperthermia Applications
- COVID-19 and Mental Health
- Hemodynamic Monitoring and Therapy
- Sarcoidosis and Beryllium Toxicity Research
- Neonatal Respiratory Health Research
- Eicosanoids and Hypertension Pharmacology
- Neuroinflammation and Neurodegeneration Mechanisms
- Cardiac Valve Diseases and Treatments
- Pharmacovigilance and Adverse Drug Reactions
- Fire effects on ecosystems
- Hepatitis C virus research
- Nursing Education, Practice, and Leadership
- Infectious Encephalopathies and Encephalitis
- Thermal Regulation in Medicine
University of Kansas Medical Center
2012-2024
University of Kansas
2010-2022
University Hospital and Clinics
2020
University Medical Center
2020
Pulmonary and Critical Care Associates
2016
ABSTRACT SARS‐CoV‐2, the causative agent of COVID‐19 disease, has resulted in death millions worldwide since beginning pandemic December 2019. While much progress been made to understand acute manifestations SARS‐CoV‐2 infection, less is known about post‐acute sequelae (PASC). We investigated levels both Spike protein (Spike) and viral RNA circulating patients hospitalized with without PASC. found that were more likely be present Among these patients, 30% positive for RNA; whereas, none...
Coronavirus disease-2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has lead to a global pandemic with rising toll in infections and deaths. Better understanding of its pathogenesis will greatly improve outcomes treatment affected patients. Here we compared inflammatory cardiovascular disease-related protein cargo circulating large small extracellular vesicles (EVs) from 84 hospitalized patients infected SARS-CoV-2 different stages disease...
HIV-associated pulmonary arterial hypertension (PAH) is likely a more prevalent noninfectious complication of AIDS than previously recognized. Furthermore, the majority HIV-PAH cases occur in individuals with history intravenous drug use. In this study we used simian immunodeficiency (SIV) macaque model and primary cell-culture system to investigate association between abuse HIV infection development.
COVID-19 infection caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic with number of deaths growing exponentially. Early evidence points to significant endothelial dysfunction, micro-thromboses, pro-inflammation as well dysregulated immune response pathogenesis this disease. In study, we analyzed cargo EVs isolated from plasma patients for identification potential biomarkers disease severity and explore their role pathogenesis....
Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and associated with interstitial lung disease in the United States. Studies have confirmed robust benefits safety of nebulized inhaled treprostinil, but it requires a time investment nebulizer preparation, maintenance, treatment. A small, portable dry powder inhaler has been developed treatment PAH. The primary objective this study was to evaluate tolerability inhalation (TreT) patients currently treated...
Section:ChooseTop of pageAbstract <<Material and MethodsResultsDiscussionReferencesCITING ARTICLES
ABSTRACT SARS-CoV-2, the causative agent of COVID-19 disease has resulted in death millions worldwide since beginning pandemic December 2019. While much progress been made to understand acute manifestations SARS-CoV-2 infection, less is known about post-acute sequelae (PASC). We investigated levels circulating components, Spike protein and viral RNA, patients hospitalized with without PASC. In (n=116), we observed a positive correlation D-dimer, length hospitalization, peak WHO score while...
Abstract Background Pulmonary hypertension due to interstitial lung disease (PH-ILD) is associated with high rates of respiratory failure and death. Healthcare resource utilization (HCRU) cost data are needed characterize PH-ILD burden. Methods A retrospective cohort analysis the Truven Health MarketScan ® Commercial Claims Encounters Database Medicare Supplemental between June 2015 2019 was conducted. Patients ILD were identified indexed based on their first claim a PH diagnosis. required...
<b>Introduction:</b> Seralutinib, a novel, inhaled kinase inhibitor with anti-inflammatory and anti-proliferative effects, met the primary endpoint of reduction in pulmonary vascular resistance phase 2 TORREY trial PAH (NCT04456998) has potential to treat remodeling. This abnormal remodeling includes distal pruning proximal arterial dilation. Quantitative analysis these features is possible CT imaging. <b>Methods:</b> The substudy used thin-section, volumetric non-contrast chest CTs followed...
SARS-CoV-2, the causative agent of COVID-19 disease has resulted in death millions worldwide since beginning pandemic December 2019. While much progress been made to understand acute manifestations SARS-CoV-2 infection, less is known about post-acute sequelae (PASC). We investigated levels circulating components, Spike protein and viral RNA, patients hospitalized with without PASC. In (n=116), we observed a positive correlation D-dimer, length hospitalization, peak WHO score while RNA...
Abstract Background Pulmonary arterial hypertension (PAH) is a progressive disease characterized by high mean pulmonary pressure (≥ 20 mmHg) and remodeling of the vascular arteries. Approved therapies improve symptoms delay clinical worsening in long term, but they do not relieve acute exertional symptoms. RT234, drug/device combination (Respira Therapeutics, Palo Alto, CA, USA) that delivers phosphodiesterase 5 inhibitor vardenafil to lungs via inhalation, has been shown reduce resistance...
<b>Background:</b> Inhaled treprostinil is currently delivered via a handheld ultrasonic nebulizer (Tyvaso<sup>®</sup> Inhalation System). A dry powder formulation of and small, portable, inhaler (Tyvaso DPI<sup>TM</sup>) in development for pulmonary arterial hypertension (PAH). <b>Objectives:</b> The primary objective was to evaluate the safety tolerability Tyvaso DPI patients previously treated with Tyvaso. Changes 6-Minute Walk Distance (6MWD), device preference satisfaction (PQ-ITD), PAH...